Tarsus Pharmaceuticals, Inc. (TARS)
NasdaqGS: TARS
· 即時價格 · USD
90.78
+7.58 (9.11%)
收盤價： Sep 04, 2026, 3:59 PM
91.18
+0.44%
盤後: 7:54 PM
股價、關鍵數字和最新消息，都在這一頁。
Tarsus Pharmaceuticals, Inc.（TARS）股價、分析與資料
9.10% (1D)
| 買價 | 64.83 |
| 市值 | 3.98B |
| 營收 (ttm) | 606M |
| 淨利（ttm） | -46.5M |
| 0.54 | |
| -1.07 | |
| n/a | |
| 39.05 | |
| P/B (ttm) | 11.33 |
| P/S (ttm) | 6.57 |
| 財報日期 | Nov 4, 2026 |
| 賣價 | 91.03 |
| 成交量 | 1,595,936 |
| 20 日平均成交量 | 975,841 |
| 開盤價 | 82.71 |
| 前收盤價 | 83.20 |
| 當日區間 | 81.07 - 91.53 |
| 52 週範圍 | 48.20 - 91.53 |
| 分析師 | 強<br>購買 |
| 目標價 | 94 (3.55%) |
| 股利 | n/a |
| 除息日 | n/a |
關於 TARS
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal h...
完整的公司簡介財務表現
Tarsus Pharmaceuticals 在 2025 年的營收為 451.36M，較前一年的 182.95M 增加 146.71%。 淨利為 -66.42M，較前期減少 -42.52%。
財務報表財報驚奇
Tarsus Pharmaceuticals 已於 Aug 6, 2026 公布季度財報：
- 營收為 $173.91M 低於預期 $0, 年增 69.41% 成長.
- 每股盈餘為 -0.43 低於預期 -0.23, 年增 10.42% 成長.
第 1 頁，共 2 頁